Journal of Transplantation / 2011 / Article / Tab 2 / Research Article
Treatment of Recurrent Focal Segmental Glomerulosclerosis
in Pediatric Kidney Transplant Recipients: Effect of Rituximab Table 2 Summary of the literature on use of rituximab in pediatric recurrent FSGS.
Age Sex Donor PP start (days posttxp) Rituximab start (days posttxp) Response Notes Nozu et al. [13 ] 12 M LRD N/A 186 CR No PP given Pescovitz et al. [16 ] 7 M DD 14 155 PR PP stopped 3 months prior to rituximab Marks and McGraw [17 ] 6 M DD 20 60 NR PP stopped 3 months prior to rituximab 10 M DD 4 294 NR Rituximab 750 mg/m2 × 2 Apeland and Hartmann [18 ] 18 M DD 7 403 CR Bayrakci et al. [19 ] 14 M LRD −5 4 CR PP started pre-txp Dello Strologo et al. [20 ] 9 — — 3629 3659 CR 13 — — 90 328 PR 7 — — 2 12 CR 12 — — 43 65 NR Hickson et al. [4 ] 19 F LRD 2 12 CR 6 M LRD −8 7 CR PP started pre-txp 13 M LRD −5 928 CR PP started pre-txp 5 M LRD −7 63 CR PP started pre-txp Grenda et al. [21 ] 5 M DD 2 90 CR PP stopped prior to rituximab
M: male; F: female; LRD: living related donor; DD: deceased donor; CR: complete response; PR: partial response; NR: no response; PP plasmapheresis. 22 ].
